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Risk factors for development of 
new skin neoplasms in patients 
with past history of skin cancer: A 
survival analysis
Ana Filipa Duarte1,2, Bernardo Sousa-Pinto  2,3,4, Eckart Haneke1,5,6,7 & Osvaldo Correia1,3,4
We conducted a retrospective study aiming to assess the risk, and associated risk factors, of developing 
subsequent skin cancers after having a first diagnosis of skin cancer. We included all patients with 
biopsy-proven skin cancer attending a dermatology clinic between July 2007 and July 2017. We 
assessed the frequency of new skin cancers, as well as potential demographic and clinical factors 
significantly associated with occurrence of such neoplasms, that were identified by means of a survival 
analysis. We analyzed 969 patients with a total of 1584 skin neoplasms (1122 basal cell carcinomas 
(BCC), 310 squamous cell carcinomas (SCC), 143 melanomas and 9 other neoplasms). 165 patients 
(17.0%) developed subsequent skin neoplasms. Factors identified in multivariable models to be 
significantly associated with development of new skin cancers included older age (adjusted HR = 1.04 
per year; 95%CI = 1.02–1.05; p < 0.001), and presence of synchronous neoplasms (adjusted HR = 2.25; 
95%CI = 1.61–3.14; p < 0.001). Having a history of a BCC was significantly associated with development 
of new BCC (adjusted HR = 1.63; 95%CI = 1.05–2.54; p = 0.030), while having a previous SCC was 
associated with occurrence of subsequent SCC (adjusted HR = 3.60; 95%CI = 1.93–6.72; p < 0.001). 
These findings point to the importance of careful follow-up (e.g., skin self-examination and full body 
examination) of skin cancer patients.
The skin is the most frequent location of primary malignant neoplasms1–3. Moreover, skin cancer incidence is 
increasing worldwide4–6. While malignant melanoma (MM) has a higher lethality than other types of skin can-
cer, non-melanoma skin cancer (NMSC) - including basal cell carcinoma (BCC) and squamous cell carcinoma 
(SCC) – is far more common and is also associated with substantial morbidity, loss of function, disfigurement, 
and costs7,8.
The follow up of patients with personal history of skin cancer has been subject of debate, particularly concern-
ing its frequency and duration9. In fact, it is known that when a patient is diagnosed for the first time with skin 
cancer, there is an increased risk of developing subsequent skin neoplasms10–12. However, this increased risk has 
been insufficiently quantified and associated epidemiological factors have not been properly identified.
Therefore, this study aims to evaluate the risk of developing a subsequent skin neoplasm after having a first 
diagnosis of skin cancer, as well as to identify potential factors associated with an increased risk of new neoplasms.
Results
Within the studied period, we assessed 969 different patients with a total of 1584 skin neoplasms (including 1122 
BCCs, 310 SCCs, 143 MMs and 9 other neoplasms); 675 patients had a single skin neoplasm, while 294 individ-
uals had more than one skin cancer. The median “free-of-new-neoplasms” follow-up time was of 45 months. 
Overall, 165 patients (17.0%; 95% CI: 14.6–19.4%) presented metachronous tumours after having been diagnosed 
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with the first one. Moreover, a total of 178 patients had synchronous neoplasms. In most cases, the type of these 
new neoplasms was the same histological type as the first assessed lesion. Therefore, of all assessed patients, a 
total of 133 developed new BCCs (13.7%; median follow-up time until a new BCC was diagnosed: 19 months), 
48 developed new SCCs (5.0%; median follow-up time: 19 months), and 7 developed new MMs (0.7%; median 
follow-up time: 50 months). Overall, the median follow-up time was of 17 months for patients who developed 
new skin neoplasms versus 11 months for the remainder. Patients’ demographic and clinical characteristics at first 
assessment are described in Table 1. Overall, patients’ age ranged between 17 and 102 years. Patients who devel-
oped new neoplasms were in average older than the remainder (69 versus 63 years, p < 0.001) and had a higher 
expression of synchronous neoplasms at first diagnosis (33.3% versus 15.3%; p < 0.001).
We performed Cox proportional hazard regression analysis to estimate variables at first assessment potentially asso-
ciated with development of new skin neoplasms (there were no significant differences in follow-up time regarding any 
of the independent variables tested). In univariable analyses, diagnosis of an SCC, older age and presence of synchro-
nous neoplasms were significantly associated with development of new skin neoplasms. However, in multivariable 
models, significant associations were only observed for age (adjusted HR = 1.04 per year; 95%CI = 1.02–1.05; p < 0.001) 
and presence of synchronous neoplasms (adjusted HR = 2.25; 95%CI = 1.61–3.14; p < 0.001) (Table 2).
Kaplan-Meier curves for development of new BCC and SCC are depicted in Fig. 1. Patients with BCC at 
first assessment had lower new BCC-free survival than the remainder (p = 0.001); accordingly, patients with 
SCC at first assessment had lower new SCC-free survival than the remaining patients (p < 0.001) (Fig. 1). In 
multivariable Cox regression models, predictive factors significantly associated with development of new BCC 
included presence of a BCC at first assessment (adjusted HR = 1.63; 95%CI = 1.05–2.54; p = 0.030), age (adjusted 
HR = 1.04 per year; 95%CI = 1.02–1.05; p < 0.001) and presence of synchronous neoplasms at first assessment 
(adjusted HR = 2.27; 95%CI = 1.55–3.32; p < 0.001) (Table 2). Regarding SCC, significant associations were also 
observed for age (adjusted HR = 1.04 per year; 95%CI = 1.01–1.07; p = 0.002) and presence of synchronous neo-
plasms at first assessment (adjusted HR = 1.93; 95%CI = 1.05–3.55; p = 0.035), as well as for presence of an SCC 
at first assessment (adjusted HR = 3.60; 95%CI = 1.93–6.72; p < 0.001) (Table 2).
Considering only patients diagnosed with a BCC within their first assessment, having a non-superficial BCC 
was associated with a decreased risk of developing a new skin cancer (HR = 0.66; 95%CI = 0.46–0.96; p = 0.027), 
including a new BCC (HR = 0.68; 95%CI = 0.46–1.00; p = 0.048). By contrast, in those patients, having a BCC 
located outside the head and neck at first assessment was significantly associated with development of new skin 
neoplasms (HR = 1.46; 95%CI = 1.01–2.11; p = 0.041), particularly new BCC (HR = 1.54; 95%CI = 1.05–2.28; 
p = 0.027). These findings are inter-related, as most superficial BCC (67.8%) were found to be located outside the 
head and neck, while most non-superficial BCC (73.7%) were located in the head or neck.
Discussion
In this study, we assessed 969 patients with skin cancer, observing that 17.0% of them developed subsequent skin 
neoplasms. Advanced age and detection of synchronous neoplasms at first diagnosis were identified as risk factors 
for the development of new skin neoplasms. In addition, patients with a past history of BCC or SCC were found 
to be at an increased risk of developing skin neoplasms of the same histological type; this association, however, 
was stronger for SCC than for BCC.
All patients 
(n = 969)
Patients with no new 
neoplasms (n = 804)
Patients with new 
neoplasms (n = 165) P valuea
Ageb – mean (SD) 64.0 (16.1) 63.0 (16.6) 69.0 (12.7)  <0.001†
Gender – n (%)
  Male 458 (47.3) 375 (46.6) 83 (50.3) 0.391*
  Female 511 (52.7) 429 (53.4) 82 (49.7)
Histological type of neoplasmsb – n (%)
  Basal cell carcinoma 665 (68.6) 548 (68.2) 117 (70.9) 0.488*
  Squamous cell carcinoma 202 (20.8) 157 (19.5) 45 (27.3) 0.026*
  Melanoma 130 (13.4) 121 (15.0) 9 (5.5) 0.001*
  Other 8 (0.8) 6 (0.7) 2 (1.2) 0.630**
Anatomical location of neoplasmsb – n (%)
  Head and neck 549 (56.7) 450 (56.0) 99 (60.0) 0.341*
  Trunk 241 (24.9) 197 (24.5) 44 (26.7) 0.558*
  Upper limb 161 (16.6) 126 (15.7) 35 (21.2) 0.082*
  Lower limb 121 (12.5) 95 (11.8) 26 (15.8) 0.163*
  Infiltrative neoplasmsb 212 (21.9) 180 (22.4) 32 (19.4) 0.397*
  Presence of synchronous neoplasmsb,c 178 (18.4) 123 (15.3) 55 (33.3) <0.001*
Table 1. Characteristics of patients when they were first diagnosed with a skin neoplasm, and comparison 
between those who subsequently developed other skin neoplasms (“patients with new neoplasms”) versus those 
who did not (“patients with no new neoplasms”). †Two-samples independent t-test; *Chi-square test; **Fisher’s 
exact test. aP values obtained by comparing patients with no new neoplasms versus patients with new neoplasms; 
bVariables assessed at the time of the first skin cancer diagnosis; cIncludes 114 patients (64.0%) with synchronous 
BCC only, 27 patients (15.2%) with synchronous SCC only, 26 patients (14.6%) with synchronous BCC and SCC, 7 
patients (3.9%) with synchronous BCC and melanoma, and 4 patients (2.2%) with synchronous melanoma only.
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Previous studies have reported the 3-year cumulative risk of a BCC or an SCC to be at least 10-fold increased 
when compared with the general population9. Our data showed a median of one year and a half for the develop-
ment of a second NMSC. Meta-analysis data revealed that the 3-year cumulative risk of an SCC is 18% after a first 
SCC and 6% after a BCC; while the 3-year cumulative risk of BCC is 44% after a first BCC or an SCC9. In a more 
recent meta-analysis, the highest risk was found for the development of subsequent cutaneous neoplasms of the 
same type10, as reported with our data. Patients who develop BCC and SCC have lower incidence of new BCC 
when compared to patients who have BCC only, possibly due to sun exposure patterns favoring SCC or to innate 
immunity trigger13.
We observed few patients developing a MM as a second neoplasm, and therefore we were not able to explore 
the potential risk factors for the occurrence of a second MM. However, the median follow-up time to the diag-
nosis of metachronous MM was above 4 years. Previous studies have reported that among MM patients, the 
incidence of a second primary MM ranges from 0.2% to 8.6%14, being higher in younger people15.
This study has some limitations, particularly as it has a retrospective design and is based on a single private 
healthcare institution which might not be representative of the whole country. Nevertheless, the demographic 
and clinical characteristics of the patients assessed are mostly consistent with those described in the literature, 
particularly concerning their mean age, gender distribution and proportion of BCC/SCC and NMSC/MM4,16,17. 
Another limitation concerns the fact that the follow-up period varied according to the time of entry into the 
study, with participants who did not develop a new skin cancer having a lower median follow-up period than 
those who did, possibly resulting in an under-estimation of the incidence of metachronous neoplasms (some 
participants might have been identified as not developing new skin tumors simply because they were early losses 
to follow-up). Finally, this study did not include the analysis of SCC precursor lesions, namely actinic keratosis.
The assessment of all patients with confirmed diagnosis of skin cancer observed in a 10 year-period is an 
important strong point of this work. In addition, we performed univariable and multivariable Cox regression 
analyses, allowing adjusted results for each tested independent variable to be obtained.
Not only did we observe a high incidence of new skin neoplasms, but also a high frequency of patients pre-
senting with more than one neoplasm at first diagnosis. In fact, almost one third of the patients that developed 
metachronous neoplasms had two or more skin neoplasms at first diagnosis. Skin cancer is an etiologically com-
plex disease with ultraviolet radiation exposure, phenotype and genotype being probably involved in the risk of 
synchronous and metachronous lesions18,19. This fact highlights the importance of registering all skin cancers, 
even if having the same histological type and/or the same location. Unfortunately, NMSC has been widely disre-
garded in national cancer registries, possibly due to their extremely high frequency and low lethality7,8, impairing 
an appropriate understanding of skin cancer epidemiology and costs.
These results, along with the finding that the presence of synchronous neoplasms is associated with a higher 
risk of developing metachronous tumors, indicate the extreme importance of a full skin body examination20 
and of a careful follow-up of skin cancer patients. Informing skin cancer patients about their risk of developing 
another skin cancer, together with teaching them skin self-examination every 1-2 months is mandatory, but it can 
cause anxiety21 if not accompanied by an easy access to physicians.
Univariable analysis: HR 
(95%CI); p value
Multivariable analysis: HR 
(95%CI); p value
All skin neoplasms
Diagnosis of a BCCa 1.30 (0.93–1.83); 0.117 —c
Diagnosis of a SCCa 1.67 (1.19–2.36); 0.005 1.03 (0.71–1.48); 0.895
Agea 1.04 (1.03–1.05); <0.001 1.04 (1.02–1.05); <0.001
Male genderb 1.27 (0.93–1.73); 0.128 1.09 (0.80–1.49); 0.590
Infiltrative neoplasma 0.78 (0.53–1.14); 0.189 —
Presence of synchronous neoplasmsa 2.92 (2.11–4.06); <0.001 2.25 (1.61–3.14); <0.001
BCC
Diagnosis of a BCCa 1.96 (1.30–2.97); <0.001 1.63 (1.05–2.54); 0.030
Agea 1.04 (1.03–1.05); <0.001 1.04(1.02–1.05); <0.001
Male genderb 1.36 (0.97–1.91); 0.079 1.18 (0.84–1.67); 0.349
Infiltrative neoplasma 0.68 (0.43–1.06); 0.076 0.71 (0.44–1.15); 0.161
Presence of synchronous neoplasmsa 2.98 (2.07–4.28); <0.001 2.27 (1.55–3.32); <0.001
SCC
Diagnosis of a SCCa 5.77(3.26–10.21); <0.001 3.60 (1.93–6.72); <0.001
Agea 1.07 (1.04–1.09); <0.001 1.04 (1.01–1.07); 0.002
Male genderb 1.40 (0.80–2.48); 0.240 —
Infiltrative neoplasma 1.55 (0.84–2.86); 0.172 —
Presence of synchronous neoplasmsa 2.64 (1.46–4.78); 0.003 1.93 (1.05–3.55); 0.035
Table 2. Results of the univariable and multivariable Cox proportional hazard regression analyses of all new 
skin neoplasms survival, new basal cell carcinomas (BCC) survival, and new squamous cell carcinomas (SCC) 
survival. HR = Hazard ratio; 95% CI = 95% confidence interval. aVariables assessed at the time of the first skin 
cancer diagnosis; bFemale gender was defined as reference category; cDiagnosis of a BCC was not introduced in 
the multivariable model, as diagnosis of a SCC was already introduced.
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Nevertheless, the adequate follow-up frequency and duration for skin cancer patients remains debatable. An 
at least annual full skin examination for 3 to 5 years for NMSC, and every 3 to 6 months, depending on stage22, for 
5 years for MM patients is desirable23. While follow-up surveillance of MM patients should be lifelong (although 
there is no international agreement for follow-up guidelines after 5 years from diagnosis)15, follow-up of NMSC 
for more than 3–5 years (3 years for BCC and 5 years for SCC) is currently not recomended9,24. This study’s 
results, however, might justify further studies to establish the best follow-up protocol for NMSC according to 
patients’ risk factors, while also emphasizing the importance of a comprehensive examination of these patients, 
assisted by dermoscopy25. This assessment is particularly important as early detection and treatment of MM and 
NMSC can reduce morbidity (and, particularly in the case of MM, mortality)26,27, bring a better health for the 
population28 and reduce the financial burden for the society29–35.
In conclusion, we observed that patients with history of skin cancer had a risk of 17.0% of developing new skin 
neoplasms, with advanced age and detection of synchronous neoplasms at first diagnosis identified as risk factors 
for the development of metachronous lesions. These findings point to the importance of total skin examination 
and careful follow-up of all skin cancer patients, including those with NMSC. Further studies are needed to eval-
uate the best follow-up protocols according to patients’ risk factors and type of neoplasms diagnosed. Meanwhile, 
teaching skin self-examination (including the most frequent benign lesions) and improving the general practi-
tioners diagnosis accuracy might improve the referral to dermatology centers, which might decrease morbidity, 
mortality and costs.
Methods
We performed a retrospective cohort study assessing all patients diagnosed with at least one biopsy-proven skin 
neoplasm between July 2007 and July 2017 in a single institution (a private dermatology center in the North of 
Portugal). For all skin neoplasms, we recorded their histological type (BCC, SCC, MM or other), their anatomical 
location (categorized as “head or neck” versus “outside the head and neck”) and whether they were or not infiltra-
tive (for BCC)/invasive (for SCC and MM). Additionally, we recorded whether each patient presented with a sin-
gle or with multiple skin neoplasms simultaneously (synchronous neoplasms) at their first assessment. For BCC, 
we also took into account its subtype – BCC subtypes were categorized as “superficial” (including superficial and 
multifocal neoplasms) or “non-superficial” (including nodular, infiltrative, and ulcerated neoplasms).
The skin cancer diagnosis was clinically performed by a senior dermatologist after full body examination, 
and was assisted by dermoscopy followed by a biopsy for histopathological diagnostic confirmation. Full body 
examination is performed in the majority of patients attending our dermatology center irrespectively of their 
initial complaint. Patients with genetic syndromes associated with multiple skin cancers and immunosuppressed 
by organ transplantation were not included. Follow-up periods were established according to the skin cancer type 
– every 6 six months for MM in the first 5 years, and thereafter annually; every 6 months for NMSC in the first 3 
years, and thereafter annually.
We assessed whether the included patients developed new cutaneous neoplasms (metachronous tumors) until 
July 2017 and recorded the diagnosis date for the first new neoplasm of each histological type. We calculated the 
Figure 1. Kaplan-Meier survival curves for diagnosis of new basal cell carcinomas (BCC) comparing patients 
who presented with BCC at first diagnostic assessment versus those who did not (A), and for diagnosis of new 
squamous cell carcinomas (SCC) comparing patients which presented with SCC at first diagnostic assessment 
versus those who did not (B). P values were obtained using log-rank test.
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skin cancer survival free time, corresponding to the time period between the date of the first diagnosed skin 
neoplasm(s) and either (i) the date of the next skin neoplasm diagnosed after the first one(s) or (ii), if no new 
skin neoplasms were detected after the first one(s), the date of the last follow-up/clinic visit. Accordingly, we also 
calculated BCC and SCC specific survivals, respectively based on the dates of the first BCC and of the first SCC 
diagnosed after the first skin neoplasm(s).
Statistical analysis. Categorical variables were described using absolute and relative frequencies, while con-
tinuous variables were described using means and standard-deviations (SD). Chi-square test and Fisher’s exact 
test were used to compare categorical variables, whereas two-independent samples t-test was used with contin-
uous variables.
We performed a Cox proportional hazard regression analysis in order to identify variables (assessed at the 
diagnosis of the first skin cancer(s)) significantly associated with occurrence of new skin neoplasms. Tested var-
iables included patients’ gender, age, diagnosis of a BCC, diagnosis of a SCC, neoplasm anatomical location, 
presentation of synchronous neoplasms, and presence of at least one infiltrative/invasive neoplasm. Firstly, we 
performed univariable analyses, and then we included all variables with at least marginal association (p < 0.150) 
with the dependent variable in a multivariable model. Similar analyses were specifically performed for the devel-
opment of new BCC and new SCC. We performed a subanalysis considering only patients with initial diagnosis 
of BCC, in order to assess whether the BCC subtype was significantly associated with development of new neo-
plasms. Results were presented using hazard ratios (HR) and 95% confidence intervals (CI).
Concerning the occurrence of new BCC, we also obtained Kaplan-Meier survival curves comparing 
patients who presented with a BCC at first diagnosis versus those who did not. For the occurrence of new SCC, 
Kaplan-Meier survival curves compared patients who presented with a SCC at first diagnosis versus those who 
did not. Comparisons were assessed using the log-rank test.
P values lower than 0.05 were considered to be statistically significant. All statistical analyses were performed 
using software R (version 3.4.3); Cox regression was performed using package ‘survival’, and Kaplan-Meier curves 
were obtained using package ‘survminer’.
Ethical approval and informed consent. All methods were carried out in accordance with relevant 
guidelines and regulations. Data analysed were fully anonymised and as such the Ethics Committee of Instituto 
CUF waived the need for approval.
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